by The global generative AI in personalized medicine market report provides a detailed analysis of the market dynamic. The report sheds light on the current situation of the market size, share, demand and forecast 2023 to 2032.
Key Takeaways:
- North America is expected to dominate in the generative AI in personalized medicine market during the forecast period.
- By personalized medicine therapeutics, the pharmaceutical segment is expected to hold a leading position in the generative AI in personalized medicine market.
- By deployment model, the cloud-based segment is expected to carry a significant share of the generative AI in personalized medicine market during the forecast period.
- By end-user, the hospitals and clinics segment shares the maximum CAGR during the projection period.
Report Summary
The global gas meter market report provides a Point-by-Point and In-Depth analysis of global market size, regional and country-level market size, market share, segmentation market growth, competitive landscape, sales analysis, opportunities analysis, strategic market growth analysis, the impact of domestic and global market key players, value chain optimization, trade regulations, recent developments, product launches, area marketplace expanding, and technological innovations.
The study offers a comprehensive analysis on diverse features, including production capacities, demand, product developments, revenue generation, and sales in the gas meter market across the globe.
A comprehensive estimate on the gas meter market has been provided through an optimistic scenario as well as a conservative scenario, taking into account the sales of gas meter during the forecast period. Price point comparison by region with global average price is also considered in the study.
Download Access to a Free Copy of Our Latest Sample Report@ https://www.precedenceresearch.com/sample/3095
Generative AI in Personalized Medicine Market Report Scope
| Report Coverage | Details |
| Largest Market | North America |
| Base Year | 2022 |
| Forecast Period | 2023 to 2032 |
| Segments Covered | By Personalized Medicine Therapeutics, By Deployment Model, and By End-User |
| Regions Covered | North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa |
Key Highlights:
Reports Coverage: It incorporates key market sections, key makers secured, the extent of items offered in the years considered, worldwide containerized gas meter market and study goals. Moreover, it contacts the division study gave in the report based on the sort of item and applications.
Market Outline: This area stresses the key investigations, market development rate, serious scene, market drivers, patterns, and issues notwithstanding the naturally visible pointers.
Market Production by Region: The report conveys information identified with import and fare, income, creation, and key players of every single local market contemplated are canvassed right now.
Also Read: Gas Meter Market Size To Cross USD 22.4 Bn By 2032
Generative AI in Personalized Medicine Market Players
The report includes the profiles of key gas meter market companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information, key development in past five years.
Major companies operating in this area
- Butterfly Network
- Deep Genomics
- Google LLC
- IBM Watson Health
- Microsoft Corporation
- Aidoc
- Insilico Medicine
- PathAI
- Tencent Holdings Ltd.
- Neuralink Corporation
- Johnson & Johnson
Market Segmentation
By Personalized Medicine Therapeutics
- Pharmaceutical
- Genomic Medicine
- Devices
By Deployment Model
- On-premise
- Cloud Based
By End-User
- Hospitals and Clinics
- Clinical Research
- Healthcare Organizations
- Diagnostic Centers
Regional Segmentation
- North America (U.S., Canada, Mexico)
- Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
- Asia-Pacific (China, Japan, India, Southeast Asia and Rest of APAC)
- Latin America (Brazil and Rest of Latin America)
- Middle East and Africa (GCC, North Africa, South Africa, Rest of MEA)
Research Methodology
Secondary Research
It involves company databases such as Hoover’s: This assists us to recognize financial information, the structure of the market participants and industry’s competitive landscape.
The secondary research sources referred in the process are as follows:
- Governmental bodies, and organizations creating economic policies
- National and international social welfare institutions
- Company websites, financial reports and SEC filings, broker and investor reports
- Related patent and regulatory databases
- Statistical databases and market reports
- Corporate Presentations, news, press release, and specification sheet of Manufacturers
Primary Research
Primary research includes face-to-face interviews, online surveys, and telephonic interviews.
- Means of primary research: Email interactions, telephonic discussions and Questionnaire-based research etc.
- In order to validate our research findings and analysis, we conduct primary interviews of key industry participants. Insights from primary respondents help in validating the secondary research findings. It also develops Research Team’s expertise and market understanding.
TABLE OF CONTENT
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology (Premium Insights)
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Generative AI in Personalized Medicine Market
5.1. COVID-19 Landscape: Generative AI in Personalized Medicine Industry Impact
5.2. COVID 19 – Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Generative AI in Personalized Medicine Market, By Personalized Medicine Therapeutics
8.1. Generative AI in Personalized Medicine Market, by Personalized Medicine Therapeutics, 2023-2032
8.1.1 Pharmaceutical
8.1.1.1. Market Revenue and Forecast (2020-2032)
8.1.2. Genomic Medicine
8.1.2.1. Market Revenue and Forecast (2020-2032)
8.1.3. Devices
8.1.3.1. Market Revenue and Forecast (2020-2032)
Chapter 9. Global Generative AI in Personalized Medicine Market, By Deployment Model
9.1. Generative AI in Personalized Medicine Market, by Deployment Model, 2023-2032
9.1.1. On-premise
9.1.1.1. Market Revenue and Forecast (2020-2032)
9.1.2. Cloud Based
9.1.2.1. Market Revenue and Forecast (2020-2032)
Chapter 10. Global Generative AI in Personalized Medicine Market, By End-User
10.1. Generative AI in Personalized Medicine Market, by End-User, 2023-2032
10.1.1. Hospitals and Clinics
10.1.1.1. Market Revenue and Forecast (2020-2032)
10.1.2. Clinical Research
10.1.2.1. Market Revenue and Forecast (2020-2032)
10.1.3. Healthcare Organizations
10.1.3.1. Market Revenue and Forecast (2020-2032)
10.1.4. Diagnostic Centers
10.1.4.1. Market Revenue and Forecast (2020-2032)
Chapter 11. Global Generative AI in Personalized Medicine Market, Regional Estimates and Trend Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Personalized Medicine Therapeutics (2020-2032)
11.1.2. Market Revenue and Forecast, by Deployment Model (2020-2032)
11.1.3. Market Revenue and Forecast, by End-User (2020-2032)
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Personalized Medicine Therapeutics (2020-2032)
11.1.4.2. Market Revenue and Forecast, by Deployment Model (2020-2032)
11.1.4.3. Market Revenue and Forecast, by End-User (2020-2032)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Personalized Medicine Therapeutics (2020-2032)
11.1.5.2. Market Revenue and Forecast, by Deployment Model (2020-2032)
11.1.5.3. Market Revenue and Forecast, by End-User (2020-2032)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Personalized Medicine Therapeutics (2020-2032)
11.2.2. Market Revenue and Forecast, by Deployment Model (2020-2032)
11.2.3. Market Revenue and Forecast, by End-User (2020-2032)
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Personalized Medicine Therapeutics (2020-2032)
11.2.4.2. Market Revenue and Forecast, by Deployment Model (2020-2032)
11.2.4.3. Market Revenue and Forecast, by End-User (2020-2032)
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Personalized Medicine Therapeutics (2020-2032)
11.2.5.2. Market Revenue and Forecast, by Deployment Model (2020-2032)
11.2.5.3. Market Revenue and Forecast, by End-User (2020-2032)
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Personalized Medicine Therapeutics (2020-2032)
11.2.6.2. Market Revenue and Forecast, by Deployment Model (2020-2032)
11.2.6.3. Market Revenue and Forecast, by End-User (2020-2032)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Personalized Medicine Therapeutics (2020-2032)
11.2.7.2. Market Revenue and Forecast, by Deployment Model (2020-2032)
11.2.7.3. Market Revenue and Forecast, by End-User (2020-2032)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Personalized Medicine Therapeutics (2020-2032)
11.3.2. Market Revenue and Forecast, by Deployment Model (2020-2032)
11.3.3. Market Revenue and Forecast, by End-User (2020-2032)
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Personalized Medicine Therapeutics (2020-2032)
11.3.4.2. Market Revenue and Forecast, by Deployment Model (2020-2032)
11.3.4.3. Market Revenue and Forecast, by End-User (2020-2032)
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Personalized Medicine Therapeutics (2020-2032)
11.3.5.2. Market Revenue and Forecast, by Deployment Model (2020-2032)
11.3.5.3. Market Revenue and Forecast, by End-User (2020-2032)
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Personalized Medicine Therapeutics (2020-2032)
11.3.6.2. Market Revenue and Forecast, by Deployment Model (2020-2032)
11.3.6.3. Market Revenue and Forecast, by End-User (2020-2032)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Personalized Medicine Therapeutics (2020-2032)
11.3.7.2. Market Revenue and Forecast, by Deployment Model (2020-2032)
11.3.7.3. Market Revenue and Forecast, by End-User (2020-2032)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Personalized Medicine Therapeutics (2020-2032)
11.4.2. Market Revenue and Forecast, by Deployment Model (2020-2032)
11.4.3. Market Revenue and Forecast, by End-User (2020-2032)
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Personalized Medicine Therapeutics (2020-2032)
11.4.4.2. Market Revenue and Forecast, by Deployment Model (2020-2032)
11.4.4.3. Market Revenue and Forecast, by End-User (2020-2032)
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Personalized Medicine Therapeutics (2020-2032)
11.4.5.2. Market Revenue and Forecast, by Deployment Model (2020-2032)
11.4.5.3. Market Revenue and Forecast, by End-User (2020-2032)
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Personalized Medicine Therapeutics (2020-2032)
11.4.6.2. Market Revenue and Forecast, by Deployment Model (2020-2032)
11.4.6.3. Market Revenue and Forecast, by End-User (2020-2032)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Personalized Medicine Therapeutics (2020-2032)
11.4.7.2. Market Revenue and Forecast, by Deployment Model (2020-2032)
11.4.7.3. Market Revenue and Forecast, by End-User (2020-2032)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Personalized Medicine Therapeutics (2020-2032)
11.5.2. Market Revenue and Forecast, by Deployment Model (2020-2032)
11.5.3. Market Revenue and Forecast, by End-User (2020-2032)
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Personalized Medicine Therapeutics (2020-2032)
11.5.4.2. Market Revenue and Forecast, by Deployment Model (2020-2032)
11.5.4.3. Market Revenue and Forecast, by End-User (2020-2032)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Personalized Medicine Therapeutics (2020-2032)
11.5.5.2. Market Revenue and Forecast, by Deployment Model (2020-2032)
11.5.5.3. Market Revenue and Forecast, by End-User (2020-2032)
Chapter 12. Company Profiles
12.1. Butterfly Network
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Deep Genomics
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Google LLC
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. IBM Watson Health
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Microsoft Corporation
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Aidoc
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Insilico Medicine
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. PathAI
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Tencent Holdings Ltd.
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Neuralink Corporation
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
Chapter 13. Research Methodology
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
Chapter 14. Appendix
14.1. About Us
14.2. Glossary of Terms
Thanks for reading you can also get individual chapter-wise sections or region-wise report versions such as North America, Europe, or the Asia Pacific.
Contact Us:
Mr. Alex
Sales Manager
Call: +1 9197 992 333
Email: sales@precedenceresearch.com
